We are live on ! Find out more
LSBPW

LakeShore Biopharma Warrants
LSBPW

Delisted

LSBPW was delisted on the 19th of September, 2025.

Back to rankings

31 hedge funds and large institutions have $3.07M invested in LakeShore Biopharma Warrants in 2023 Q1 according to their latest regulatory filings, with 31 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
31
Holders Change
+31
Holders Change %
–
% of All Funds
0.49%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
31
Increased
–
Reduced
–
Closed
–
Calls
$185K
Puts
–
Net Calls
+$185K
Net Calls Change
+$185K

Top Buyers

Rank Fund Capital Flow
1
LP
LMR Partners
United Kingdom
+$159K
2
VAM
Valliance Asset Management
Hong Kong
+$114K
3
BP
BFAM Partners
Hong Kong
+$83.3K
4
Jane Street
Jane Street
New York
+$75.5K
5
FC
Finepoint Capital
Massachusetts
+$74.2K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
26
Elequin Capital
New York
$5.84K +$5.68K +37,500 New
MC
27
Meteora Capital
Florida
$3.89K +$3.79K +25,000 New
SIA
28
SkyView Investment Advisors
New Jersey
$2K +$1.85K +12,210 New
LCM
29
Landscape Capital Management
New Jersey
$1.56K +$1.51K +10,000 New
HIM
30
HGC Investment Management
Ontario, Canada
$1K +$758 +5,000 New
AA
31
Ancora Advisors
Ohio
$786 +$765 +5,050 New
TRCT
32
Tower Research Capital (TRC)
New York
– +$19 +126 New
1
2

LSBPW Hedge Fund Activity: Q1 2023 in Review

31 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma Warrants (LSBPW) for Q1 2023, worth a combined $3.07M.

Buyers outnumbered sellers: 31 funds opened new LSBPW positions and 0 closed out — a net gain of 31 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was LMR Partners, opening a new position worth an estimated $159K.

  • 31 institutional investors held LakeShore Biopharma Warrants (LSBPW) as of Q1 2023, up from 0 in Q4 2022.
  • Funds reported $3.07M of LakeShore Biopharma Warrants stock for Q1 2023.
  • 31 funds opened new LakeShore Biopharma Warrants positions in Q1 2023 and 0 closed out, a net change of +31 holders.
  • The largest LakeShore Biopharma Warrants buyer in Q1 2023 was LMR Partners, an estimated $159K added.

Based on aggregated 13F filings for Q1 2023.